Breast Cancer Research and Treatment

, Volume 47, Issue 2, pp 129–140 | Cite as

Expression of multiple apoptosis-regulatory genes in human breast cancer cell lines and primary tumors

  • Juan M. Zapata
  • Maryla Krajewska
  • Stanislaw Krajewski
  • Ruo-Pan Huang
  • Shinichi Takayama
  • Hong-Gang Wang
  • Eileen Adamson
  • John C. Reed


The expression of several apoptosis-regulating genes was evaluated in 9 human breast cancer cell lines, 2 immortalized human mammary epithelial lines, 1 normal breast tissue biopsy, and 3 primary breast tumors, using a multiple antigen detection (MAD) immunoblotting method. The anti-apoptotic proteins Bcl-2, Bcl-XL, Mcl-1, and BAG-1 were present at immunodetectable levels in 7, 10, 10, and 9 of the 11 lines. Comparing these 11 cell lines among themselves revealed that steady-state levels of Bcl-2, Bcl-XL, Mcl-1, and BAG-1 were present at relatively higher levels in 4, 6, 5, and 5 of the lines, respectively. In contrast, the pro-apoptotic proteins Bax and Bak were detected in all 11 cell lines, and were present at relatively higher levels in 10 and 5 of the 11 lines, respectively. The Interleukin-1β converting enzyme (ICE) homolog CPP32 (Caspase-3) was expressed in 10/11 breast cell lines. High levels of p53 protein, indicative of mutant p53, were found in 8 of the 11 lines and correlated inversely with Bax expression (p=0.01). Bcl-2 and BAG-1 protein levels were positively correlated (p = 0.03). Immunoblot analysis of primary adenocarcinomas revealed expression of the anti-apoptotic proteins Bcl-2, Bcl-XL, Mcl-1, and BAG-1, as well as the pro-apoptotic proteins Bax, Bak, and CPP32, in at least 2 of the 3 tumors examined. Immunohistochemical analysis was also performed for all of these proteins using 20 paraffin-embedded breast cancer biopsy specimens that all contained residual normal mammary epithelium in combination with both invasive cancer and carcinoma in situ. All of these apoptosis-regulating proteins were detected in primary breast cancers, though the percentage of immunopositive tumor cells varied widely in some cases. Comparisons of the intensity of immunostaining in normal mammary epithelium and invasive carcinoma suggested that Bcl-2 immunointensity tends to be lower in cancers than normal breast epithelium (p=0.03), whereas CPP32 immunointensity was generally higher in invasive cancers (p < 0.0001). Taken together, the results demonstrate expression of multiple apoptosis-modulating proteins in breast cancer cell lines and primary tumors, suggesting complexity in the regulation of apoptosis in these neoplasms of mammary epithelial origin.

apoptosis BAG-1 Bak Bax Bcl-2 Bcl-XL caspase-3 Mcl-1 breast cell lines breast tumors 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Nowell PC: The clonal evolution of tumor cell populations. Science 194: 23–28, 1976Google Scholar
  2. 2.
    Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1–6, 1994Google Scholar
  3. 3.
    Reed JC: Bcl-2: Prevention of apoptosis as a mechanism of drug resistance. Hematology/Oncology Clinics of North America 9: 451–474, 1995Google Scholar
  4. 4.
    Vaux DL, Haecker G, Strasser A: An evolutionary perspective on apoptosis. Cell 76: 777–779, 1994Google Scholar
  5. 5.
    Reed JC: Regulation of apoptosis by Bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 7: 541–546, 1995Google Scholar
  6. 6.
    Patel T, Gores GJ, Kaufmann SH: The role of proteases during apoptosis. FASEB J 10: 587–597, 1996Google Scholar
  7. 7.
    Steck S, McDonnell T, Sneige N, El-Naggar A: Flow cytometry analysis of apoptosis and Bcl-2 in primary breast carcinomas: clinical and biological implications. Cytometry 24: 116–122, 1996Google Scholar
  8. 8.
    Neville MC, Daniel CW: The Mammary Gland: Development, Regulation and Function. Plenum Publishing, 1987Google Scholar
  9. 9.
    Wang TTY, Phang JM: Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res 55: 2487–2489, 1995Google Scholar
  10. 10.
    Shibata M-A, Maroulakou IG, Jorcyk CL, Gold LG, Ward JM, Green JE: p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma. Cancer Res 56: 2998–3003, 1996Google Scholar
  11. 11.
    Pullan S, Wilson J, Metcalfe A, Edwards GM, Goberdhan N, Tilly J, Hickman JA, Dive C, Streuli CH: Requirement of basement membrane for the suppression of programmed cell death in mammary epithelium. J Cell Science 109: 631–642, 1996Google Scholar
  12. 12.
    Wingo PA, Tong T, Bolden S: Cancer Statistics, 1995. CA, Cancer J Clinic 45: 8–30, 1995Google Scholar
  13. 13.
    Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Reihsaus E, Kynch HT, Marcus JN, Schwartz L, Chen L-C, Mayall BH, Smith HS: Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 84: 845–855, 1992Google Scholar
  14. 14.
    Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of human bax gene. Cell 80: 293–299, 1995Google Scholar
  15. 15.
    Krajewski S, Blomvqvist C, Franssila K, Krajewska M, Wasenius V-M, Niskanen E, Reed JC: Reduced expression of pro-apoptotic gene Bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55: 4471–4478, 1995Google Scholar
  16. 16.
    Krajewski S, Chatten J, Hanada M, Womer R, Reed JC: Immunohistochemical analysis of the Bcl-2 oncoprotein in human neuroblastoma. Lab Invest 71: 42–54, 1995Google Scholar
  17. 17.
    Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA, Reed JC: Cloning and functional analysis of BAG-1: a novel Bcl-2 binding protein with anti-cell death activity. Cell 80: 279–284, 1995Google Scholar
  18. 18.
    Boudreau N, Sympson CJ, Werb Z, Bissell MJ: Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 267: 891–893, 1995Google Scholar
  19. 19.
    Krajewski S, Bodrug S, Gascoyne R, Berean K, Krajewska M, Reed JC: Immunohistochemical analysis of mcl-1 and bcl-2 proteins in normal and neoplastic lymph nodes. Amer J Pathol 145: 515–525, 1994Google Scholar
  20. 20.
    Krajewski S, Gascoyne RD, Zapata JM, Krajewska M, Kitada S, Chhanabhai M, Horsman D, Berean K, Piro LD, Fugier-Vivier I, Liu YJ, Wang HG, Reed JC: Immunolocalization of the ICE/Ced-3-family protease, CPP32 (Caspase-3), in non-Hodgkin's lymphomas (NHLs), chronic lymphocytic leukemias (CLL), and reactive lymph nodes. Blood 89: 3817–3825, 1997Google Scholar
  21. 21.
    Krajewski S, Krajewska M, Reed JC: Immunohistochemical analysis of in vivo patterns of Bak expression, a pro-apoptotic member of the Bcl-2 protein family. Cancer Res 56: 2849–2855, 1996Google Scholar
  22. 22.
    Krajewski S, Krajewska M, Shabaik A, Wang H-G, Irie S, Fong L, Reed JC: Immunohistochemical analysis of in vivo patterns of Bcl-X expression. Cancer Res 54: 5501–5507, 1994Google Scholar
  23. 23.
    Reed JC, Yum S, Cuddy MP, Turner BC, Rapp UR: Differential regulation of the p72–74 Raf-1 kinase by RAS and SRC oncoproteins. Cell Growth & Diff 2: 235–243, 1991Google Scholar
  24. 24.
    Takayama S, Kochel K, Irie S, Inazawa J, Abe T, Sato T, Druck T, Huebner K, Reed JC: Cloning of cDNAs encoding human BAG1 protein and localization of the human BAG1 gene to chromosome 9p12. Genomics 35: 494–498, 1996Google Scholar
  25. 25.
    Krajewski S, Zapata JM, Reed JC: Detection of multiple antigens on Western blots. Anal Biochem 236: 221–228, 1996Google Scholar
  26. 26.
    Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang H-G, Reed JC: Immunohistochemical determination of in vivo distribution of bax, a dominant inhibitor of bcl-2. Am J Pathol 145: 1323–1333, 1994Google Scholar
  27. 27.
    Reed JC, Krajewski S, Kitada S, Miyashita T: Methods of measuring Bcl-2 gene expression. In: Herzenberg LA et al (ed) Handbook of Experimental Immunology, 5th edition, Vol. 3, pp 128.1–128.11, 1996Google Scholar
  28. 28.
    Guan RJ, Moss SF, Arber N, Krajewski S, Reed JC, Holt PR: 30 kDa phosphorylated form of Bcl-2 protein in human colon. Oncogene 12: 2605–2609, 1996Google Scholar
  29. 29.
    Bartek J, Iggo R, Gannon J, Lane DP: Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 5: 893–899, 1990Google Scholar
  30. 30.
    Runnebaum IB, Nagarajan M, Bowman M, Soto D, Sukumar S: Mutations in p53 as potential molecular markers for human breast cancer. Proc Natl Acad Sci USA 88: 10657–10661, 1991Google Scholar
  31. 31.
    Sabourin JC, Martin A, Baruch J, Truc JB, Gompel A, Poitout P: bcl-2 expression in normal breast tissue during the menstrual cycle. Int J Cancer 59: 1–6, 1994Google Scholar
  32. 32.
    Krajewska M, Wang H-G, Krajewski S, Zapata J, Shabaik A, Gascoyne R, Reed JC: Immunohistochemical analysis of in vivo patterns of expression of CPP32 (Caspase-3), a cell death protease. Cancer Res 57: 1605–1613, 1997Google Scholar
  33. 33.
    Reed JC: Balancing cell life and death: Bax, apoptosis, and breast cancer. J Clin Invest 97: 2403–2404, 1996Google Scholar
  34. 34.
    Casey G, Lo-Hsueh M, Lopez ME, Vogelstein B, Stanbridge EJ: Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. Oncogene 6: 1791–1797, 1991Google Scholar
  35. 35.
    Krajewski S, Thor AD, Edgerton SU, Moore DH, Krajewska N, Reed JC: Immunohistochemical analysis of Bax and Bcl-2 in p53-immunopositive breast cancers. Clin Cancer Res 3: 199–208, 1996Google Scholar
  36. 36.
    Bargou RC, Daniel PT, Mapara MY, Bommert K, Wagener C, Kallinich B, Royer HD, Dörken B: Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-??expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer 60: 854–859, 1995Google Scholar
  37. 37.
    Wagener C, Bargou RC, Daniel PT, Bommert K, Mapara MY, Royer HD, Dörken B: Induction of the death-promoting gene bax-alpha sensitizes cultured breast-cancer cells to drug-induced apoptosis. Int J Cancer 67: 138–141, 1996Google Scholar
  38. 38.
    Miyashita T, Kitada S, Krajewski S, Horne B, Delia D, Reed JC: Overexpression of the Bcl-2 protein increases the halflife of p21-Bax. J Biol Chem 270: 26049–26052, 1995Google Scholar
  39. 39.
    Takayama S, Bimston DN, Matsuzawa S, Freeman BC, Aime-Sempe C, Xie Z, Morimoto RJ, Reed JC: BAG-1 modulates the chaperone activity of Hsp70/Hsc70. EMBO J in press, 1997Google Scholar
  40. 40.
    Zeinet M, Gehring U: A protein that interacts with members of the nuclear hormone receptor family: identification and cDNA cloning. Proc Natl Acad Sci USA 92: 11465–11469, 1995Google Scholar
  41. 41.
    Wang H-G, Takayama S, Rapp UR, Reed JC: Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1. Proc Natl Acad Sci USA 93: 7063–7068, 1996Google Scholar

Copyright information

© Kluwer Academic Publishers 1998

Authors and Affiliations

  • Juan M. Zapata
  • Maryla Krajewska
  • Stanislaw Krajewski
  • Ruo-Pan Huang
  • Shinichi Takayama
  • Hong-Gang Wang
  • Eileen Adamson
  • John C. Reed

There are no affiliations available

Personalised recommendations